FIELD: experimental pharmacology.
SUBSTANCE: invention relates to experimental pharmacology, namely to a method for creating an experimental model of Parkinson’s disease. For this purpose, mice are once subcutaneously injected with a type 2 monoamine vesicular transporter inhibitor tetrabenazine at a dosage of 12 mg per 1 animal.
EFFECT: invention makes it possible to more accurately reproduce pathological processes in Parkinson’s disease, which in the future may create conditions for the development of a fundamentally new class of antiparkinsonian drugs.
1 cl, 3 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENTS FOR USE IN PREVENTING AND/OR TREATING HYPERKINETIC MOTOR DISORDERS | 2014 |
|
RU2685502C2 |
| METHOD OF CORRECTION OF OXIDATIVE STATUS IN PARKINSON'S DISEASE IN EXPERIMENT | 2023 |
|
RU2800859C1 |
| ANALOGUES OF CYSTAMINE, USED FOR PARKINSON'S DISEASE TREATMENT | 2012 |
|
RU2630583C2 |
| METHOD FOR EARLY DIAGNOSIS OF PARKINSON'S DISEASE | 2019 |
|
RU2722666C1 |
| METHOD OF CORRECTING TREMOR IN EXPERIMENT | 2018 |
|
RU2678977C1 |
| N-ALKYL-TROPINES AND N-ALKYL-NORTROPINES HAVING h-LYTIC, ANTIPARKINSONIAN, ANTIEPILEPTIC, ANALGESIC AND ANTIDEPRESSANT ACTIVITY | 2014 |
|
RU2597616C2 |
| METHOD FOR OBTAINING AN AGENT FOR BLOCKING EXPERIMENTAL PARKINSONISM | 2017 |
|
RU2675697C2 |
| TREATMENT OF NEUROLOGICAL DISEASES | 2017 |
|
RU2755997C2 |
| USE OF LACTOBACILLUS FERMENTUM U-21 STRAIN CELLS FOR PREVENTION OF PATHOLOGIC TISSUE CHANGE CAUSED BY OXIDATIVE STRESS | 2019 |
|
RU2757118C2 |
| METHOD FOR DIAGNOSING PARKINSON'S DISEASE ASSOCIATED WITH MUTATIONS IN GLUCOCEREBROSIDASE (GBA) GENE | 2020 |
|
RU2750357C1 |
